Novartis Pharmaceuticals UK Ltd

Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Patient Information Leaflet last updated on the eMC: 07/04/2011
PIL DIOVAN Capsules

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 07/04/2011 and displayed until Current
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to side-effects
Updated on 14/10/2009 and displayed until 07/04/2011
Reasons for adding or updating:
  • Change due to harmonisation of PIL.
  • Change to date of revision
Updated on 30/01/2009 and displayed until 14/10/2009
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 15/08/2008 and displayed until 30/01/2009
Reasons for adding or updating:
  • Change to packaging
  • Change of inactive ingredient
Updated on 04/01/2008 and displayed until 15/08/2008
Reasons for adding or updating:
  • Introduction of new pack/pack size
Updated on 28/09/2007 and displayed until 04/01/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to information about pregnancy or lactation
  • Change to side-effects
  • Change to instructions about overdose
Updated on 08/01/2007 and displayed until 28/09/2007
Reasons for adding or updating:
  • Change to drug interactions
Updated on 10/12/2004 and displayed until 08/01/2007
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   valsartan